Expansion of pan‐cancer mismatch repair testing: Implications for pembrolizumab eligibility and Lynch syndrome screening

CancerEarly View LETTER TO THE EDITOR Expansion of pan-cancer mismatch repair testing: Implications for pembrolizumab eligibility and Lynch syndrome screening This article relates to: Reply to "Expansion of pan-cancer mismatch repair testing: Implications for pembrolizumab eligibility and Lynch syndrome screening" Teresa S. Chai MS, Linda H. Rodgers-Fouche MGC, Anthony R. Mattia MD, Daniel C. Chung MD, Cancer First Published online: October 29, 2024 Chong-jie Zhang MM, Chong-jie Zhang MM orcid.org/0009-0003-4017-1357 Department of Colorectal Surgery, Ningbo No. 2 Hospital,, Ningbo, Zhejiang Province, ChinaSearch for more papers by this author Chong-jie Zhang MM, Chong-jie Zhang MM orcid.org/0009-0003-4017-1357 Department of Colorectal Surgery, Ningbo No. 2 Hospital,, Ningbo, Zhejiang Province, ChinaSearch for more papers by this author First published: 29 October 2024 https://doi.org/10.1002/cncr.35624Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Chai TS, Rodgers-Fouche LH, Walls JO, Mattia AR, Chung DC. Real-world genetic testing outcomes of pan-cancer testing for mismatch repair deficiency. Cancer. Published online 2024. doi:10.1002/cncr.35473 10.1002/cncr.35473 Google Scholar 2Moslim MA, Heald B, Tu C, Burke CA, Walsh RM. Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer. Surgery. 2018; 164(4): 754-759. doi:10.1016/j.surg.2018.05.059 10.1016/j.surg.2018.05.059 PubMedGoogle Scholar 3Cremin C, Lee MK, Hong Q, et al. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med. 2020; 9(11): 4004-4013. doi:10.1002/cam4.2973 10.1002/cam4.2973 CASPubMedWeb of Science®Google Scholar 4Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2020; 6: 414-438. doi:10.1200/jgo.19.00367 10.1200/JGO.19.00367 PubMedWeb of Science®Google Scholar 5Buonaiuto R, Neola G, Caltavituro A, et al. Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type. Front Oncol. 2024; 14:1412807. doi:10.3389/fonc.2024.1412807 10.3389/fonc.2024.1412807 PubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation